STUDY OF EFFECT OF NEPEFENAC ON SWELLING OF CENTRAL RETINA AFTER CATARACT SURGERY.

COMPARISON OF EFFECT OF 0.1% VERSUS 0.3% NEPAFENAC ON CHANGES IN MACULAR AND CHOROIDAL THICKNESS AFTER CATARACT SURGERY IN PATIENTS WITH DIABETES MELLITUS.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/028097

Enrollment

Registered

2020-09-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H590- Disorders of the eye following cataract surgery

Interventions

Intervention1: ADMINISTRATION OF NEPAFENAC: SUBJECTS ARE DIVIDED INTO 2 EQUAL GROUPS. ONE GROUP IS ADMINISTERED WITH 0.1 % NEPAFENAC TID AND ANOTHER GROUP WITH 0.3% NEPAFENAC OD FOR 2 WEEKS POSTOPERA

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with type 2 diabetes mellitus undergoing cataract surgery All patients of age ranging from 40 â?? 70 years Patients with Uneventful cataract surgery with intraocular lens ( IOL) in bag Image quality > 40 Patients who are willing for follow up.

Exclusion criteria

Exclusion criteria: Patients diagnosed with Complicated cataract Mature cataract Uveitic cataract Macular edema at baseline Glaucoma associated with cataract Posterior capsular defect Intraocular lens in sulcus. Patients on treatment for macular edema in the past 3 months. Patients on anti -glaucoma drugs. Cases with unusual post-op inflammation. Other retinal pathologies requiring treatment / compromising vision. Deviation from the specified technique of surgery. Cases requiring YAG capsulotomy within the follow up period. Patients not willing for follow up according to fixed schedule. Cases who require laser photocoagulation in last 3 months.

Design outcomes

Primary

Measure	Time frame
To compare the effect of 0.1% versus 0.3% Nepafenac in changes in macular thickness after cataract surgery in diabetes patients. Timepoint: preoperatively and postoperatively at 1 week,1 month and 3 months.	—

Secondary

Measure	Time frame
To compare the effect of 0.1% versus 0.3% Nepafenac in changes in choroidal thickness after cataract surgery in diabetes patients To compare the visual outcome following cataract surgery in diabetic patients. Timepoint: preoperatively and postoperatively at 1 week, 1 month and 3 months.	—

Countries

India

Contacts

Public ContactDR DEEPIKA V

SANKARA EYE HOSPITAL, SHIVAMOGGA

maheshbhat@sankaraeye.com9611115608

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026